Melvin H. Hayes III - 09 Aug 2022 Form 3 Insider Report for Fulcrum Therapeutics, Inc. (FULC)

Role
Chief Operating Officer
Signature
/s/ Gregory Tourangeau, as attorney-in-fact for Melvin Hayes
Issuer symbol
FULC
Transactions as of
09 Aug 2022
Net transactions value
$0
Form type
3
Filing time
11 Aug 2022, 16:10:15 UTC
Next filing
13 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding FULC No securities are beneficially owned 0 09 Aug 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding FULC Stock Option (right to buy) 09 Aug 2022 Common Stock 140,000 $28.49 Direct F1
holding FULC Stock Option (right to buy) 09 Aug 2022 Common Stock 50,000 $12.69 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person received an option to purchase a total of 140,000 shares on September 7, 2021. The shares underlying the option are scheduled to vest 25% on the first anniversary of the vesting commencement date of September 7, 2021. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service.
F2 The reporting person received an option to purchase a total of 50,000 shares on January 19, 2022. The shares underlying the option are scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2022, subject to continued service.

Remarks:

Exhibit Index: 24.1 Power of Attorney